title: Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
abstract: BACKGROUND
  Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases.
  
  
  METHODS
  We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns.
  
  
  CONCLUSIONS
  These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed.
authors.affiliation: Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Room 12N238, 10 Center Dr, Bethesda, MD 20892, USA. konghe@mail.nih.gov
authors.forename: Heidi H
authors.initials: HH
authors.lastname: Kong
authors.forename: Howard A
authors.initials: HA
authors.lastname: Fine
authors.forename: Jere B
authors.initials: JB
authors.lastname: Stern
authors.forename: Maria L Chanco
authors.initials: ML
authors.lastname: Turner
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017484:Dermatitis, Phototoxic / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000473:pathology; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012867:Skin / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011799:Quinazolines; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; C452423:vandetanib
references.citation: Lancet Oncol. 2005 Jul;6(7):491-500
references.pmid: 15992698
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4270-7
references.pmid: 17878479
references.citation: J Surg Res. 2005 Dec;129(2):251-9
references.pmid: 16140331
references.citation: J Thorac Oncol. 2008 Apr;3(4):386-93
references.pmid: 18379357
references.citation: Am J Clin Dermatol. 2001;2(4):253-62
references.pmid: 11705252
references.citation: J Thorac Oncol. 2006 Nov;1(9):1002-9
references.pmid: 17409986